Regardless of what’s happening elsewhere in the market, biopharma is a great place to look for stocks to pack into your portfolio because there’s always an illness that can be treated more effectively in the future than it is being treated today.
Our stock pick features an established drug maker with an excellent approval history. Their treatments have been widely trusted for years, and currently, they have multiple promising projects in the pipeline.
The 12-million-mile battery that already exists…
This technology already exists, and it’s rolling out to manufacturers at this moment. The one company behind it is on the cusp of an enormous surge… [Click here for the full story…]
Drugmaker, Viatris (VTRS) is profitable and looking for more growth. The company is in the process of trimming its less-profitable operations, including its biosimilars, women’s health division, and its over-the-counter drugs. In its place, it is adding an ophthalmology franchise through the $750 million acquisitions of Oyster Point Pharma and Famy Life Sciences. The deal is expected to close in the first quarter of 2023. Management expects the acquisition to generate at least $1 billion in sales by 2028.
[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”VTRS” start_expanded=”true” display_currency_symbol=”true” api=”yf”]